

Whereas May 1, 2020, is an appropriate date to designate as “Silver Star Service Banner Day”: Now, therefore, be it

*Resolved*, That the Senate—

- (1) supports the designation of May 1, 2020, as “Silver Star Service Banner Day”; and
- (2) calls upon the people of the United States to observe Silver Star Service Banner Day with appropriate programs, ceremonies, and activities.

**SENATE RESOLUTION 586—DESIGNATING THE WEEK OF MAY 17 THROUGH MAY 23, 2020, AS “NATIONAL PUBLIC WORKS WEEK”**

Mr. INHOFE (for himself, Ms. HARRIS, Mr. BARRASSO, Mr. CARPER, Mrs. CAPITO, Mr. CARDIN, Mr. BLUMENTHAL, Mr. BOOZMAN, Mr. CASSIDY, Mr. CRAMER, Ms. DUCKWORTH, Ms. HASSAN, Mr. KING, Mr. MARKEY, Mrs. SHAHEEN, Mrs. FISCHER, and Mrs. FEINSTEIN) submitted the following resolution; which was considered and agreed to:

S. RES. 586

Whereas public works infrastructure, facilities, and services are of vital importance to the health, safety, and well-being of the people of the United States;

Whereas public works infrastructure, facilities, and services could not be provided without the dedicated efforts of public works professionals, including engineers and administrators, who represent State and local governments throughout the United States;

Whereas public works professionals design, build, operate, and maintain the transportation systems, water infrastructure, sewage and refuse disposal systems, public buildings, sanitation and waste management systems, and other structures and facilities that are vital to the people and communities of the United States;

Whereas, during the ongoing COVID-19 pandemic, public works professionals have continued to provide essential services, placing themselves at increased risk of infection; and

Whereas understanding the role that public infrastructure plays in protecting the environment, improving public health and safety, contributing to economic vitality, and enhancing the quality of life of every community of the United States is in the interest of the people of the United States: Now, therefore, be it

*Resolved*, That the Senate—

(1) designates the week of May 17 through May 23, 2020, as “National Public Works Week”;

(2) recognizes and celebrates the important contributions that public works professionals make every day to improve—

(A) the public infrastructure of the United States; and

(B) the communities that public works professionals serve; and

(3) urges individuals and communities throughout the United States to join with representatives of the Federal Government and the American Public Works Association in activities and ceremonies that are designed—

(A) to pay tribute to the public works professionals of the United States; and

(B) to recognize the substantial contributions that public works professionals make to the United States.

**SENATE RESOLUTION 587—EXPRESSING SUPPORT FOR THE DESIGNATION OF MAY 17, 2020, AS “DIPG PEDIATRIC BRAIN CANCER AWARENESS DAY” TO RAISE AWARENESS OF AND ENCOURAGE RESEARCH ON DIFFUSE INTRINSIC PONTINE GLIOMA TUMORS AND PEDIATRIC CANCERS IN GENERAL**

Mr. RUBIO (for himself, Mr. REED, Mrs. HYDE-SMITH, Mr. CASEY, and Mr. BRAUN) submitted the following resolution; which was considered and agreed to:

S. RES. 587

Whereas diffuse intrinsic pontine glioma (referred to in this preamble as “DIPG”) tumors regularly affect 200 to 400 children in the United States each year;

Whereas brain tumors are the leading cause of cancer-related death among children;

Whereas, during childhood, DIPG tumors are—

(1) the second most common type of malignant brain tumor; and

(2) the leading cause of pediatric brain cancer deaths;

Whereas, with respect to a child who is diagnosed with a DIPG tumor and receives treatment for a DIPG tumor, the median amount of time that the child survives after diagnosis is only 9 months;

Whereas, with respect to an individual who is diagnosed with a DIPG tumor, the rate of survival 5 years after diagnosis is approximately 2 percent;

Whereas the average age at which a child is diagnosed with a DIPG tumor is between 5 and 9 years, resulting in a life expectancy approximately 70 years shorter than the average life expectancy in the United States; and

Whereas the prognosis for children diagnosed with DIPG tumors has not improved over the past 40 years: Now, therefore, be it

*Resolved*, That the Senate—

(1) supports—

(A) designating May 17, 2020, as “DIPG Pediatric Brain Cancer Awareness Day”; and

(B) efforts to—

(i) better understand diffuse intrinsic pontine glioma tumors;

(ii) develop effective treatments for diffuse intrinsic pontine glioma tumors; and

(iii) provide comprehensive care for children with diffuse intrinsic pontine glioma tumors and their families; and

(2) encourages all individuals in the United States to become more informed about—

(A) diffuse intrinsic pontine glioma tumors;

(B) pediatric brain cancer in general; and

(C) challenges relating to research on pediatric cancers and ways to advance such research.

**SENATE RESOLUTION 588—DESIGNATING MAY 2020 AS “ALS AWARENESS MONTH”**

Mr. BRAUN (for himself, Mr. COONS, Mr. COTTON, Mr. BENNET, Ms. MCSALLY, Mr. DURBIN, Mr. BOOZMAN, Mr. JONES, Mr. WHITEHOUSE, Mr. BLUMENTHAL, Mr. PETERS, Ms. SINEMA, Mr. VAN HOLLEN, Mr. WYDEN, Ms. SMITH, Mrs. HYDE-SMITH, Ms. MURKOWSKI, Mr. JOHNSON, Mrs. SHAHEEN, Mr. SCOTT of South Carolina, Mr. SCHUMER, Ms. ROSEN, Mr. CRAMER, Ms. HARRIS, Mr. LANKFORD, Mr. MARKEY, Ms. CANTWELL, and Ms. KLOBUCHAR) submitted the following

resolution; which was considered and agreed to:

S. RES. 588

Whereas amyotrophic lateral sclerosis (referred to in this preamble as “ALS”) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord;

Whereas the life expectancy for an individual with ALS is between 2 and 5 years after the date on which the individual receives an ALS diagnosis;

Whereas ALS occurs throughout the world with no racial, ethnic, gender, or socioeconomic boundaries;

Whereas the 2 different types of ALS are sporadic ALS and familial ALS;

Whereas sporadic ALS—

(1) is the most common form of motor neuron disease in the United States;

(2) accounts for between 90 and 95 percent of all cases of ALS in the United States; and

(3) may affect any individual in any location;

Whereas familial ALS (commonly known as “FALS”)—

(1) is inherited; and

(2) accounts for between 5 and 10 percent of all cases of ALS in the United States;

Whereas there is a 50 percent chance that each offspring of an individual with familial ALS will inherit the gene mutation for familial ALS and develop the disease;

Whereas, on average, the period between the date on which an individual first experiences symptoms of ALS and the date on which the individual is diagnosed with ALS is about 1 year;

Whereas the onset of ALS often involves muscle weakness or stiffness, and the progression of ALS results in the further weakening, wasting, and paralysis of—

(1) the muscles of the limbs and trunk; and

(2) the muscles that control vital functions, such as speech, swallowing, and breathing;

Whereas ALS can strike individuals of any age but predominantly strikes adults;

Whereas it is estimated that tens of thousands of individuals in the United States have ALS at any given time;

Whereas, based on studies of the population of the United States, slightly more than 5,600 individuals in the United States are diagnosed with ALS each year, and 15 individuals in the United States are diagnosed with ALS each day;

Whereas, between 2015 and 2040, the number of ALS cases around the world is expected to increase nearly 70 percent;

Whereas the majority of individuals with ALS die of respiratory failure;

Whereas military veterans are approximately twice as likely to be diagnosed with ALS than the general public in the United States;

Whereas, as of the date of introduction of this resolution, there is no cure for ALS;

Whereas the spouses, children, and family members of individuals living with ALS provide support to those individuals with love, day-to-day care, and more; and

Whereas an individual with ALS, and the caregivers of such an individual, can be required to bear significant costs for medical care, equipment, and home health care services for the individual as the disease progresses: Now, therefore, be it

*Resolved*, That the Senate—

(1) designates May 2020 as “ALS Awareness Month”;

(2) affirms the dedication of the Senate to working toward securing cures and better treatments for amyotrophic lateral sclerosis (referred to in this resolution as “ALS”) as soon as possible;

(3) recognizes the challenges that individuals with medically determined ALS face on a daily basis; and

(4) commends the dedication of the family members, friends, organizations, volunteers, researchers, and caregivers across the United States that are working to improve the quality and length of life of ALS patients.

#### AMENDMENTS SUBMITTED AND PROPOSED

SA 1588. Mr. BRAUN submitted an amendment intended to be proposed by him to the bill S. 658, to provide for an accelerated approval pathway for certain drugs that are authorized to be lawfully marketed in other countries; which was referred to the Committee on Health, Education, Labor, and Pensions.

#### TEXT OF AMENDMENTS

**SA 1588.** Mr. BRAUN submitted an amendment intended to be proposed by him to the bill S. 658, to provide for an accelerated approval pathway for certain drugs that are authorized to be lawfully marketed in other countries; which was referred to the Committee on Health, Education, Labor, and Pensions; as follows:

Strike all after the enacting clause and insert the following:

##### SECTION 1. SHORT TITLE.

This Act may be cited as the "Accelerated Drug Approval for Prescription Therapies Act" or the "ADAPT Act".

##### SEC. 2. ACCELERATED APPROVAL OF CERTAIN DRUGS THAT ARE AUTHORIZED TO BE LAWFULLY MARKETED IN OTHER COUNTRIES.

Chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended by inserting after section 506 the following:

##### "SEC. 506-1. ACCELERATED APPROVAL OF CERTAIN DRUGS THAT ARE AUTHORIZED TO BE LAWFULLY MARKETED IN OTHER COUNTRIES.

"(a) IN GENERAL.—The Secretary may approve an application for approval for a drug or vaccine under subsection (c) or (j) of section 505 of this Act or under subsection (a) or (k) of section 351 of the Public Health Service Act that is currently authorized to be marketed in one or more of the countries included in the list under section 802(b)(1) or the United Kingdom, upon a determination by the Secretary that the sponsor has submitted evidence sufficient to demonstrate all of the criteria under subsection (b)(1).

##### "(b) CRITERIA.—

"(1) IN GENERAL.—The Secretary may approve a drug or vaccine under subsection (a) only if the Secretary determines that there is evidence that—

"(A) at the time of application, the drug or vaccine is authorized to be marketed in a country included in the list under section 802(b)(1) or the United Kingdom;

"(B) the drug or vaccine is safe and clinically effective;

"(C) the manufacturer is capable of manufacturing the drug or vaccine safely and consistently, and can assure the safety of the supply chain outside the United States;

"(D) all relevant United States patents or legal exclusivities are expired;

"(E) absent reciprocal marketing approval, the drug or vaccine is not approved for marketing in the United States;

"(F) the Secretary has not, because of any concern relating to safety or effectiveness, rescinded or withdrawn any such approval; and

"(G) the drug or vaccine is intended for the treatment or prevention of a disease or condition that poses a threat of epidemic or pandemic, including with respect to the coronavirus, or the drug is intended to treat the coronavirus, including reduced risk of death, severe disease, and progression of symptoms in individuals exposed to the virus.

"(2) LIMITATION.—Approval of a drug or vaccine under this section may, as the Secretary determines appropriate, be subject to 1 or both of the following requirements:

"(A) The sponsor conduct appropriate post-approval studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit of the drug or vaccine.

"(B) The sponsor submit copies of all promotional materials related to the product during the preapproval review period and, following approval and for such period thereafter as the Secretary determines to be appropriate, at least 30 days prior to dissemination of the materials.

##### "(c) TIMELINE.—

"(1) IN GENERAL.—The Secretary shall make a determination on an application described in subsection (a) not later than 30 days after the date of submission of such application.

"(2) REVIEW OF APPLICATIONS DURING EPIDEMICS AND PANDEMICS.—In the case of an epidemic or pandemic, including with respect to the coronavirus, the Secretary shall accept and review various portions of an application submitted under this section on a rolling basis, and the review of any part of an application so submitted shall be completed not later than 3 weeks after submission.

"(d) CORONAVIRUS DEFINED.—The term 'coronavirus' means SARS-CoV-2, COVID-19, or another coronavirus with epidemic potential.

##### "(e) REAL-TIME EPIDEMIC AND PANDEMIC VACCINE APPROVAL.—

"(1) IN GENERAL.—In the case of a vaccine approved under the authority of this section that is intended to treat or prevent diseases or conditions that pose a threat of an epidemic or pandemic, including the coronavirus, the Secretary shall share data information regarding the approval of the vaccine with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention as the review nears completion.

"(2) EVALUATION.—Any vaccine that has been approved under the authority of this section for an epidemic or pandemic-related disease or condition, including the coronavirus, shall be evaluated by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention not later than 1 week after the date of submission to the Advisory Committee by the Secretary of the vaccine."

#### AUTHORITY FOR COMMITTEES TO MEET

Mr. THUNE. Mr. President, I have 3 requests for committees to meet during today's session of the Senate. They have the approval of the Majority and Minority leaders.

Pursuant to rule XXVI, paragraph 5(a), of the Standing Rules of the Senate, the following committees are authorized to meet during today's session of the Senate:

#### COMMITTEE ON BANKING, HOUSING, AND URBAN AFFAIRS

The Committee on Banking, Housing, and Urban Affairs is authorized to

meet during the session of the Senate on Tuesday, May 19, 2020, at 10 a.m., to conduct a hearing.

#### SELECT COMMITTEE ON INTELLIGENCE

The Select Committee on Intelligence is authorized to meet during the session of the Senate on Tuesday, May 19, 2020, at 9:30 a.m., to conduct a hearing.

#### SUBCOMMITTEE ON CLEAN AIR AND NUCLEAR SAFETY

The Subcommittee on Clean Air and Nuclear Safety of the Committee on Environment and Public Works is authorized to meet during the session of the Senate on Tuesday, May 19, 2020, at 3 p.m., to conduct a hearing on the following nominations: Beth Harwell and Brian Noland to be Members of the Board of Directors, and Katherine Crytzer to be Inspector General of the Tennessee Valley Authority.

Mr. INHOFE. Mr. President, I have a request for one committee to meet during today's session of the Senate. It has the approval of the Majority and Minority leaders.

Pursuant to rule XXVI, paragraph 5(a), of the Standing Rules of the Senate, the following committee is authorized to meet during today's session of the Senate:

#### COMMITTEE ON ARMED SERVICES

The Committee on Armed Services is authorized to meet during the session of the Senate on Tuesday, May 19, 2020, at 2:30 p.m., to conduct a hearing on nominations.

#### RESOLUTIONS SUBMITTED TODAY

Mr. MCCONNELL. Mr. President, I ask unanimous consent that the Senate now proceed to the en bloc consideration of the following Senate resolutions which were submitted earlier today: S. Res. 584, S. Res. 585, S. Res. 586, S. Res. 587, and S. Res. 588.

There being no objection, the Senate proceeded to consider the resolutions en bloc.

Mr. MCCONNELL. Mr. President, I ask unanimous consent that the resolutions be agreed to, the preambles, where applicable, be agreed to, and the motions to reconsider be considered made and laid upon the table, all en bloc.

The PRESIDING OFFICER. Is there objection?

Without objection, it is so ordered.

The resolution (S. Res. 584) was agreed to.

(The resolution is printed in today's RECORD under "Submitted Resolutions.")

The resolutions (S. Res. 585, S. Res. 586, S. Res. 587, and S. Res. 588) were agreed to.

The preambles were agreed to.

(The resolutions, with their preambles, are printed in today's RECORD under "Submitted Resolutions.")

#### ORDERS FOR WEDNESDAY, MAY 20, 2020

Mr. MCCONNELL. Mr. President, I ask unanimous consent that when the